Literature DB >> 21700592

Pneumothorax associated with treatment for pulmonary malignancy.

Tomohiro Maniwa1, Kazuo Nakagawa, Mitsuhiro Isaka, Yasuhisa Ohde, Takehiro Okumura, Haruhiko Kondo.   

Abstract

Pneumothorax associated with treatment for pulmonary malignancy (PATPM) is a rare complication. Its clinicopathological features have not yet been clearly defined. Forty-one patients with PATPM from September 2002 to March 2009 were included. We evaluated the clinicopathological findings and treatment outcome of these patients. Of the 41 patients, 21 had primary lung cancer and 20 had metastatic lung tumours. Twenty-four patients (58.5%) required chest tube drainage for more than six days. Ten patients (24%) finally, received surgical treatment. Regarding the surgical procedure, conversion to open thoracotomy was required in seven (70%) of these 10 patients because of dense adhesions or anatomical changes in the thoracic cavity caused by treatment or the progression of the tumours. Two patients had severe complications after surgery. One of these two patients and another patient died of primary disease within 30 days after surgery. The median survival time in the 10 patients with surgery was 223 days (range 22-1059 days). PATPM tends to require chest tube drainage for a long period, and sometimes needs surgical treatment, which may be difficult. We should carefully identify patients who would derive considerable benefit from surgical treatment.

Entities:  

Mesh:

Year:  2011        PMID: 21700592     DOI: 10.1510/icvts.2011.273201

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's condition.

Authors:  Manfred Hauben; Eric Y Hung
Journal:  Int J Med Sci       Date:  2013-06-13       Impact factor: 3.738

2.  Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.

Authors:  Rodrigo B Interiano; M Beth McCarville; Jianrong Wu; Andrew M Davidoff; John Sandoval; Fariba Navid
Journal:  J Pediatr Surg       Date:  2015-01-16       Impact factor: 2.545

3.  Pneumothorax during Pemetrexed Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report and Literature Review.

Authors:  Yoshiro Nakahara; Shinichiro Mikura; Makoto Nagamata; Tomoya Fukui; Jiichiro Sasaki; Noriyuki Masuda
Journal:  Case Rep Oncol       Date:  2017-05-09

4.  Clinical characteristics and outcome of pneumothorax after stereotactic body radiotherapy for lung tumors.

Authors:  Kaori Asai; Katsumasa Nakamura; Yoshiyuki Shioyama; Tomonari Sasaki; Yoshio Matsuo; Saiji Ohga; Tadamasa Yoshitake; Kotaro Terashima; Makoto Shinoto; Keiji Matsumoto; Hidenari Hirata; Hiroshi Honda
Journal:  Int J Clin Oncol       Date:  2015-04-28       Impact factor: 3.402

5.  Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma.

Authors:  Spyridon Gennatas; Susana J Stanway; Robert Thomas; Toon Min; Riyaz Shah; Mary E R O'Brien; Sanjay Popat
Journal:  BMC Cancer       Date:  2013-04-26       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.